Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Short-term studies have shown that bempedoic acid, an inhibitor of ATP citrate lyase, reduces levels of low-density lipoprotein (LDL) cholesterol. Data are limited regarding the safety and efficacy of bempedoic acid treatment in long-term studies involving patients with hypercholesterolemia who are receiving guideline-recommended statin therapy. METHODS: We conducted a randomized, controlled trial involving patients with atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, or both. Patients had to have an LDL cholesterol level of at least 70 mg per deciliter while they were receiving maximally tolerated statin therapy with or without additional lipid-lowering therapy. (Maximally tolerated statin therapy was defined as the highest intensity statin regimen that a patient was able to maintain, as determined by the investigator.) Patients were randomly assigned in a 2:1 ratio to receive bempedoic acid or placebo. The primary end point was safety, and the principal secondary end point (principal efficacy end point) was the percentage change in the LDL cholesterol level at week 12 of 52 weeks. RESULTS: The trial involved 2230 patients, of whom 1488 were assigned to receive bempedoic acid and 742 to receive placebo. The mean (±SD) LDL cholesterol level at baseline was 103.2±29.4 mg per deciliter. The incidence of adverse events (1167 of 1487 patients [78.5%] in the bempedoic acid group and 584 of 742 [78.7%] in the placebo group) and serious adverse events (216 patients [14.5%] and 104 [14.0%], respectively) did not differ substantially between the two groups during the intervention period, but the incidence of adverse events leading to discontinuation of the regimen was higher in the bempedoic acid group than in the placebo group (162 patients [10.9%] vs. 53 [7.1%]), as was the incidence of gout (18 patients [1.2%] vs. 2 [0.3%]). At week 12, bempedoic acid reduced the mean LDL cholesterol level by 19.2 mg per deciliter, representing a change of -16.5% from baseline (difference vs. placebo in change from baseline, -18.1 percentage points; 95% confidence interval, -20.0 to -16.1; P<0.001). Safety and efficacy findings were consistent, regardless of the intensity of background statin therapy. CONCLUSIONS: In this 52-week trial, bempedoic acid added to maximally tolerated statin therapy did not lead to a higher incidence of overall adverse events than placebo and led to significantly lower LDL cholesterol levels. (Funded by Esperion Therapeutics; CLEAR Harmony ClinicalTrials.gov number, NCT02666664.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The CLEAR Harmony trial assessed bempedoic acid’s safety and efficacy in 2230 statin-treated patients with atherosclerosis or HeFH compared with placebo [130]. Relative to placebo, bempedoic acid reduced LDL-C by − 16%, non-HDL-C by − 13%, total cholesterol by − 11%, ApoB-100 by − 12% and hsCRP by − 22%.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [130]
In the citing paper
“The incidence of adverse events was similar across both interventional groups, yet a higher percentage discounted treatment with bempedoic acid than placebo (10.9% versus 7.1%). Gout was more frequently observed among patients treated with bempedoic acid (1.2% versus 0.3%).”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [130]
In the citing paper
“Clinical trials have shown bempedoic acid reduces LDL-C levels and the CLEAR Outcomes trial demonstrated a significant reduction in MACE compared with placebo in patients who are statin intolerant [[12], [13], [14], [15],17].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [14]
In the citing paper
“Safety findings in the real-world setting were generally aligned with those reported in RCTs and meta-analyses [[12], [13], [14], [15],17,18], although reporting was limited and inconsistently captured.”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [14]
In the citing paper
“The overall risk of bias was low 7 of 11 trials [7, 9–12, 15, 16], with 4 trials being assessed as having a moderate risk of bias [8, 13, 14, 17].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [12]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Enzymatic Determination of Total Serum Cholesterol
Allain, C. C., Poon, L. S., Chan, C. S. G., Richmond, W., & Fu, P. C. (1974) · Clinical Chemistry · doi:10.1093/clinchem/20.4.470 · Cited by 9,125
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Self-citationSerum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide.
Fossati, P., & Prencipe, L. (1982) · Clinical Chemistry · doi:10.1093/clinchem/28.10.2077 · Cited by 2,905
Explaining the decrease in U.S. deaths from coronary disease, 1980–2000
Ford, E. S., Ajani, U. A., Croft, J. B., Critchley, J. A., Labarthe, D. R., Kottke, T. E., Giles, W. H., & Capewell, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa053935 · Cited by 2,757
A peroxidase-coupled method for the colorimetric determination of serum triglycerides.
McGowan, M. W., Artiss, J. D., Strandbergh, D. R., & Zak, B. (1983) · Clinical Chemistry · doi:10.1093/clinchem/29.3.538 · Cited by 1,298
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 773
Self-citationPinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhotak, S., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., et al. (2016) · Nature Communications · doi:10.1038/ncomms13457 · Cited by 498
Self-citationBallantyne, C. M., Banach, M., Mancini, G. B. J., Lepor, N. E., Hanselman, J. C., Zhao, X., & Leiter, L. A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.002 · Cited by 422
Self-citationMendelian Randomization Study of ACLY and Cardiovascular Disease
Ference, B. A., Ray, K. K., Catapano, A. L., Ference, T. B., Burgess, S., Neff, D. R., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., Di Angelantonio, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1806747 · Cited by 342
Self-citation
Cited by
Items 201–300 of 807
Landscape of Statin as a Cornerstone in Atherosclerotic Cardiovascular Disease
Yang, C., Wu, Y., Qian, J., & Li, J. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2412373 · Cited by 31
Mansfield, B. S., Mohamed, F., Larouche, M., & Raal, F. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144160 · Cited by 31
“When added to maximally tolerated statin therapy, bempedoic acid reduces LDL-C by between 16 and 18% [33,34].”
BackgroundEvaluation and management of blood lipids through a woman's life cycle
Sharma, J., McAlister, J., Aggarwal, N. R., Wei, J., Mehta, P. K., Quesada, O., Mattina, D. J., Scott, N. S., Michos, E. D., Mahmoud, Z., et al. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100333 · Cited by 35
Burnett, H. F., Fahrbach, K. R., Cichewicz, A. B., Jindal, R., Tarpey, J., Durand, A., Domenico, M. D., Reichelt, A., & Viljoen, A. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2049164 · Cited by 36
Kumrić, M., Urlić, H., Božić, J., Vilović, M., Kurir, T. T., Glavaš, D., Miric, D., Zanchi, J., Bradarić, A., Lozo, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098062 · Cited by 28
Broader Perspective on Atherosclerosis—Selected Risk Factors, Biomarkers, and Therapeutic Approach
Fularski, P., Czarnik, W., Dąbek, B., Lisińska, W., Radzioch, E., Witkowska, A., Młynarska, E., Rysz, J., & Franczyk, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105212 · Cited by 30
“The CLEAR Harmony and CLEAR Wisdom trials were randomized, double-blind, placebo-controlled phase 3 clinical trials investigating the safety and efficacy of bempedoic acid in patients with hypercholesterolemia and a high risk of CVD [111,112].”
BackgroundMethodLipid-lowering therapy and percutaneous coronary interventions
Koskinas, K. C., Mach, F., & Räber, L. (2021) · EuroIntervention · doi:10.4244/eij-d-20-00999 · Cited by 32
Bays, H. E., Baum, S. J., Brinton, E. A., Plutzky, J., Hanselman, J. C., Teng, R., & Ballantyne, C. M. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100278 · Cited by 25
Self-citationManagement of patients with statin intolerance
Martirossian, A. N., & Goldberg, A. C. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101714 · Cited by 28
Stroes, E. S. G., Bays, H. E., Banach, M., Catapano, A. L., Duell, P. B., Laufs, U., Mancini, G. B. J., Ray, K. K., Sasiela, W. J., Zhang, Y., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.020 · Cited by 29
Self-citationBayesian Analytical Methods in Cardiovascular Clinical Trials: Why, When, and How
Heuts, S., Kawczynski, M. J., Sayed, A., Urbut, S., Albuquerque, A. M., Mandrola, J. M., Kaul, S., Harrell, F. E., Gabrio, A., & Brophy, J. M. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.11.002 · Cited by 48
Wang, S., Qin, L., Liu, F., & Zhang, Z. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02169-0 · Cited by 25
“It is worth noting that bempedoic acid (BemA), an ACLY inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) to reduce low-density lipoprotein cholesterol recently [307].”
Bempedoic Acid: A Promising Novel Agent for LDL-C Lowering
Agarwala, A., & Goldberg, A. C. (2020) · Future Cardiology · doi:10.2217/fca-2020-0016 · Cited by 28
Dyslipidemia Management in 2020: An Update on Diagnosis and Therapeutic Perspectives
Karantas, I. D., Okur, M. E., Okur, N. Ü., & Siafaka, P. I. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200810144004 · Cited by 33
New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia
Pirillo, A., & Catapano, A. L. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000706 · Cited by 29
“4%, respectively) [15,16], that were lower than those observed when bempedoic acid was added to”
BackgroundSelf-citationSAMSON and the Nocebo Effect: Management of Statin Intolerance
Krishnamurthy, A., Bradley, C., Ascunce, R. R., & Kim, S. M. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01729-x · Cited by 25
New algorithms for treating homozygous familial hypercholesterolemia
Tromp, T. R., & Cuchel, M. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000853 · Cited by 27
“It was recently approved by the FDA and EMA and has been shown to lower LDL-C by approximately 18% on top of maximally tolerated LLT [47,48].”
BackgroundFatty acid metabolism: A new therapeutic target for cervical cancer
Ping, P., Li, J., Lei, H., & Xu, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1111778 · Cited by 36
“A variety of ACLY inhibitors have been used to treat hyperlipidemia (82, 83).”
BackgroundAberrant Lipid Metabolism in Cancer: Current Status and Emerging Therapeutic Perspectives
Irshad, R., Tabassum, S., & Husain, M. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230522103321 · Cited by 34
Structure of ACLY in complex with CoA
Wei, X., & Marmorstein, R. (2019) · Worldwide Protein Data Bank · doi:10.2210/pdb6poe/pdb · Cited by 24
Ferri, N., Colombo, E., & Corsini, A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111371 · Cited by 27
Emerging lipid lowering agents targeting LDL cholesterol
Wójcik, C. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1751422 · Cited by 23
Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside
Agarwala, A., Quispe, R., Goldberg, A. C., & Michos, E. D. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s251865 · Cited by 23
“3% in the bempedoic acid vs placebo arms, respectively.(28) In CLEAR Wisdom, hyperuricemia was also seen more commonly with bempedoic acid (4.”
BackgroundMethodInfluentialEvaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia
Cicero, A. F. G., Fogacci, F., & Cincione, R. I. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1951222 · Cited by 27
Grande, F., Occhiuzzi, M. A., Perri, M. R., Ioele, G., Rizzuti, B., Statti, G. A., & Garofalo, A. (2021) · Molecules · doi:10.3390/molecules26185718 · Cited by 25
“Very recently, bempedoic acid, a prodrug with inhibitory activity on adenosine triphosphate citrate lyase, another hepatic enzyme involved in cholesterol biosynthesis, has been introduced into clinical practice [5].”
BackgroundAtherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China
Bi, L., Yi, J., Wu, C., Hu, S., Zhang, X., Lu, J., Liu, J., Zhang, H., Yang, Y., Cui, J., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.839571 · Cited by 25
Dyslipidemia in Renal Transplant Recipients
Chmielnicka, K., Heleniak, Z., & Dębska-Ślizień, A. M. (2022) · Transplantology · doi:10.3390/transplantology3020020 · Cited by 29
“In December 2022, outcomes of the CLEAR trial will reveal if bempedoic acid lowers CVD incidence in patients with statin intolerance [88].”
BackgroundWang, P., Hou, T., Xu, F., Luo, F., Zhou, H., Liu, F., Xie, X., Liu, Y., Wang, J., Guo, Z., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810747 · Cited by 23
“Flavonoids as ACLY inhibitors were structurally different from the reported inhibitors, such as the well-known Medica–16 [16], clinically used Nexletol [13], and SB–204990 [17], which share a terminal carboxyl group, and were also different from the more active 2hydroxy-N-arylbenzenesulfonamides inhibitors BMS–303141…”
BackgroundInfluentialNew Therapeutic Approaches to the Treatment of Dyslipidemia 2: LDL-C and Lp(a)
Kim, K. A., & Park, H. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.37 · Cited by 22
Management of Lipid Abnormalities in Patients with Diabetes
Sillars, A., & Sattar, N. A. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1246-1 · Cited by 24
Alsayed, N., Almahmeed, W. A., Alnouri, F., Al-Waili, K., Sabbour, H. M., Sulaiman, K., Zubaid, M., Ray, K. K., & Al‐Rasadi, K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.11.022 · Cited by 25
Self-citationTong, J., Wang, Z., Zhang, J., Gao, R., Liu, X., Liao, Y., Guo, X., & Wei, Y. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c13607 · Cited by 23
Ballantyne, C. M., & Norata, G. D. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf606 · Cited by 26
Self-citationKim, E. J., & Wierzbicki, A. S. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320924569 · Cited by 22
Blaum, C. M., Brunner, F. J., Goßling, A., Kroeger, F., Bay, B., Lorenz, T., Graef, A., Zeller, T., Schnabel, R. B., Clemmensen, P. M., et al. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.07.019 · Cited by 24
Bempedoic Acid: An Emerging Therapy for Uncontrolled Low-Density Lipoprotein (LDL) Cholesterol
Pradhan, A. K., Bhandari, M., Vishwakarma, P., Singh, A., Perrone, M. A., & Sethi, R. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10050195 · Cited by 25
Albuquerque, E. L., Fulco, U. L., Caetano, E. W. S., & Freire, V. N. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108774956.011 · Cited by 21
Mendelian Randomization Study of ACLY and Cardiovascular Disease. Reply.
Ference, B. A., Ray, K. K., & Nicholls, S. J. (2020) · PubMed · doi:10.1056/nejmc1908496 · Cited by 13
Zhang, X., Qin, Y., Wan, X., Liu, H., Iv, C., Ruan, W., Lü, L., He, L., & Guo, X. (2020) · BioMed Research International · doi:10.1155/2020/5036572 · Cited by 30
Umbrella Review on Non-Statin Lipid-Lowering Therapy
Beshir, S. A., Hussain, N., Elnour, A. A., & Said, A. S. A. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211002943 · Cited by 23
“However, even in the cases of optimal statin use, there is a residual risk of ASCVD.”
BackgroundInfluentialKatzmann, J. L., Becker, C., Bilitou, A., & Laufs, U. (2022) · PLoS ONE · doi:10.1371/journal.pone.0276898 · Cited by 21
Review of recent clinical trials and their impact on the treatment of hypercholesterolemia
Parham, J. S., & Goldberg, A. C. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.11.011 · Cited by 24
Greco, A., Finocchiaro, S., Angiolillo, D. J., & Capodanno, D. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2171788 · Cited by 23
“Bempedoic acid, an oral inhibitor of adenosine triphosphate citrate lyase, was investigated in the CLEAR Harmony trial: 2,230 patients with either or both atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia were randomized to bempedoic acid or placebo (2:1 ratio) on top of maximally to…”
MethodPerera, K., Kam, N., Ademi, Z., Liew, D., & Zomer, E. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.08.013 · Cited by 22
The year in cardiology: cardiovascular prevention
Ray, K. K., Laufs, U., Cosentino, F., Lobo, M. D., & Landmesser, U. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz929 · Cited by 20
Self-citationAngina in 2022: Current Perspectives
Manfredi, R., Verdoia, M., Compagnucci, P., Barbarossa, A., Stronati, G., Casella, M., Russo, A. D., Guerra, F., & Ciliberti, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11236891 · Cited by 27
“Inclisiran and bempedoic acid have been proven effective in reducing LDL cholesterol of approximately 50% and 16%, respectively, when compared to placebo [41,42].”
BackgroundTherapeutic strategies targeting metabolic characteristics of cancer cells
Bai, R., Meng, Y., & Cui, J. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104037 · Cited by 25
Ruiz, H. H., López‐Díez, R., Arivazahagan, L., Ramasamy, R., & Schmidt, A. M. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312005 · Cited by 26
“Human genetic data(78) and data from subjects receiving bempedoic acid suggest links of this ACLY inhibitor to metabolic improvements with reduction in levels of LDL (low-density lipoprotein) cholesterol.(79) In a study in mice devoid of the Ldlr and fed a high-fat and high-cholesterol diet, treatment of the mice for…”
BackgroundSayed, A., Shazly, O., Slipczuk, L., Krittanawong, C., Baloch, F., & Virani, S. S. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07474-9 · Cited by 19
“The overall risk of bias was low 7 of 11 trials [7, 9–12, 15, 16], with 4 trials being assessed as having a moderate risk of bias [8, 13, 14, 17 ].”
Zhao, X., Ma, X.-B., Luo, X., Shi, Z., Deng, Z., Jin, Y., Xiao, Z., Tan, L., Liu, P., Jiang, S., et al. (2020) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-020-00463-w · Cited by 21
Sola‐García, A., Cáliz‐Molina, M. Á., Espadas, I., Petr, M. A., Panadero‐Morón, C., González-Morán, D., Martín-Vázquez, M. E., Narbona‐Pérez, Á. J., López–Noriega, L., Corrales, G. M., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04625-4 · Cited by 24
Sun, L., Wolska, A. T., Amar, M. J., Zubirán, R., & Remaley, A. T. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad153 · Cited by 27
Recent advances in the management and implementation of care for familial hypercholesterolaemia
Lan, N. S. R., Bajaj, A., Watts, G. F., & Cuchel, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106857 · Cited by 22
Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
Mohamed, F., Mansfield, B. S., & Raal, F. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155082 · Cited by 22
“Trials such as CLEAR Harmony and CLEAR Wisdom enrolled participants with established ASCVD and/or heterozygous FH (HeFH), most of whom were already taking high-intensity statins [5,29].”
MethodFularski, P., Hajdys, J., Majchrowicz, G., Stabrawa, M., Młynarska, E., Rysz, J., & Franczyk, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031637 · Cited by 28
“These drugs were frequently used in children with FH, since they are not systemically absorbed [100].”
BackgroundČeška, R., Latkovskis, G., Владиславович, Е. М., Freiberger, T., Lalic, K. S., Mitchenko, O., Paragh, G., Petrulionienė, Ž., Pojskić, B., Rašlová, K., et al. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0797-3 · Cited by 22
Lipid-modifying therapy in chronic kidney disease: Pathophysiological and clinical considerations
Heine, G. H., Eller, K., Stadler, J. T., Rogacev, K. S., & Marsche, G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107459 · Cited by 20
Novel Experimental Agents for the Treatment of Hypercholesterolemia
Pećin, I., & Reiner, Ž. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s267376 · Cited by 22
Ray, K. K. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1008 · Cited by 20
Self-citationStroke Genetics: Turning Discoveries into Clinical Applications
Dichgans, M., Beaufort, N., Debette, S., & Anderson, C. D. (2021) · Stroke · doi:10.1161/strokeaha.121.032616 · Cited by 21
Wan, J., Jiang, C.-X., Tang, Y., Ma, G.-L., Tong, Y., Jin, Z., Zang, Y., Osman, E. E. A., Li, J. X., Xiong, J., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105630 · Cited by 19
Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk
Rikhi, R. R., & Shapiro, M. D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154611 · Cited by 19
“The safety and efficacy of bempedoic acid has been described in recent phase 3 Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) trials [9,11,38,39].”
BackgroundMethodInfluentialMetabolism-based approaches for autosomal dominant polycystic kidney disease
Bakaj, I., & Pocai, A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1126055 · Cited by 22
“No major safety concerns were identified for BA in a randomized controlled phase III trial during the intervention period when added to statin therapy, but the incidence of AEs leading to discontinuation was higher in the BA group, as was the incidence of gout (Ray et al., 2019).”
BackgroundAmore, B. M., Cramer, C. T., MacDougall, D. E., & Emery, M. G. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.122.001142 · Cited by 19
Present and Future of Dyslipidaemia Treatment—A Review
Merćep, I., Vujević, A., Strikić, D., Radman, I. B., Pećin, I., & Reiner, Ž. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185839 · Cited by 25
Bhagavathula, A. S., Matrooshi, N. O. A., Clark, C. C. T., & Rahmani, J. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00989-1 · Cited by 20
Influence of lipid-lowering drugs on inflammation: what is yet to be done?
Ugovšek, S., Zupan, J., Likozar, A. R., & Šebeštjen, M. (2021) · Archives of Medical Science · doi:10.5114/aoms/133936 · Cited by 23
“Furthermore, in four phase 3 randomised clinical trials, bempedoic acid provided significant reductions in LDL cholesterol levels: CLEAR Harmony (NCT02666664) [13]; CLEAR Wisdom (NCT029911118) [18]; CLEAR Tranquility (NCT03001076) [82]; and CLEAR Serenity (NCT02988115) [17].”
BackgroundMaximizing the benefits of cholesterol-lowering drugs
Feingold, K. R. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000631 · Cited by 19
Hussain, A., & Ballantyne, C. M. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-100119-013612 · Cited by 22
Self-citationJia, X., & Virani, S. S. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012352 · Cited by 20
“authors pointed out, this may simply be a statistical anomaly as previous studies, including the phase 3 safety trial, did not show a treatment-related increase in cardiovascular events or mortality in the bempedoic acid group.(14)”
Bempedoic Acid: A New Tool in the Battle Against Hyperlipidemia
Powell, J., & Piszczatoski, C. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.12.001 · Cited by 19
Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2022
Orozco‐Beltrán, D., Cuixart, C. B., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Rioboó, E. M., Baldó, A. J., Vicuña, J., & Pérez, J. N. (2022) · Atención Primaria · doi:10.1016/j.aprim.2022.102444 · Cited by 80
Zhou, P., Huang, T., Ma, G., Tong, Y., Chen, W., Zang, Y., Xiong, J., Li, J. X., & Hu, J. (2023) · Journal of Natural Products · doi:10.1021/acs.jnatprod.3c00040 · Cited by 17
Genomic Innovation in Early Life Cardiovascular Disease Prevention and Treatment
Li, C., Pan, Y., Zhang, R., Huang, Z., Li, D., Han, Y., Larkin, C. T., Rao, V., Sun, X., & Kelly, T. N. (2023) · Circulation Research · doi:10.1161/circresaha.123.321999 · Cited by 22
Mutschlechner, D., Tscharre, M., Huber, K., & Gremmel, T. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad052 · Cited by 20
Development of New Genome Editing Tools for the Treatment of Hyperlipidemia
Preta, G. (2023) · Cells · doi:10.3390/cells12202466 · Cited by 19
Tarugi, P., Bertolini, S., Calandra, S., Arca, M., Angelico, F., Casula, M., Cefalu, A. B., D’Erasmo, L., Fortunato, G., Filardi, P. P., et al. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.05.002 · Cited by 20
Self-citationColivicchi, F., Fusco, S. A. D., Scicchitano, P., Caldarola, P., Murrone, A., Valente, S., Urbinati, S., Roncon, L., Amodeo, V., Aspromonte, N., et al. (2020) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001108 · Cited by 24
Ten things to know about ten cardiovascular disease risk factors (“ASPC Top Ten – 2020”)
Bays, H. E. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100003 · Cited by 20
“Patients with FH who do not achieve their LDL cholesterol treatment goals with maximally tolerated high intensity statins may benefit from adding proprotein convertase subtilisin kexin 9 inhibitors, bempedoic acid, ezetimibe (alone or combined with bempedoic acid), or other lipid-altering drugs (e.g., bile acid seques…”
BackgroundSelf-citationAberrant Energy Metabolism in Tumors and Potential Therapeutic Targets
Fan, S., Guo, J., Nie, H., Xiong, H., & Xia, Y. (2024) · Genes Chromosomes and Cancer · doi:10.1002/gcc.70008 · Cited by 21
Burger, A. L., Pogran, E., Muthspiel, M., Kaufmann, C. C., Jäger, B., & Huber, K. (2022) · Biomedicines · doi:10.3390/biomedicines10050970 · Cited by 17
“In contrast to statins, myopathy seems to be insignificant during bempedoic acid treatment [13,50].”
BackgroundMethodInfluentialBonaventura, A., Moroni, F., Golino, M., Buono, M. G. D., Vecchié, A., Potere, N., & Abbate, A. (2023) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.23.06390-1 · Cited by 21
Goyal, A., Changez, M. I. K., Tariq, M. D., Mushtaq, F., Shamim, U., Sohail, A. H., & Mahalwar, G. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102236 · Cited by 18
Management of dyslipidemia in coronary artery disease: the present and the future
Dimitriadis, K. S., Theofilis, P., Iliakis, P., Pyrpyris, N., Dri, E., Sakalidis, A., Σουλαϊδόπουλος, Σ., Tsioufis, P., Fragkoulis, C., Chrysohoou, C. A., et al. (2024) · Coronary Artery Disease · doi:10.1097/mca.0000000000001375 · Cited by 23
LDL-Cholesterol-Lowering Therapy
Pirillo, A., Norata, G. D., & Catapano, A. L. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_361 · Cited by 18
Self-citationWomen and diabetes: preventing heart disease in a new era of therapies
Galati, G., Sabouret, P., Germanova, O., & Bhatt, D. L. (2021) · European Cardiology Review · doi:10.15420/ecr.2021.22 · Cited by 15
Effect of Bempedoic Acid on atherogenic lipids and inflammation: A meta-analysis
Masson, W. M., Lobo, M., Cobo, A. L., & Molinero, G. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.09.002 · Cited by 17
Patel, P. N., & Giugliano, R. P. (2020) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2020.39 · Cited by 24
Abushanab, D., Al‐Badriyeh, D., Marquina, C., Bailey, C., Jaam, M. J., Liew, D., & Ademi, Z. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101211 · Cited by 17
Bempedoic Acid: Lipid Lowering for Cardiovascular Disease Prevention
Albosta, M. S., Grant, J. K., & Michos, E. D. (2023) · Heart International · doi:10.17925/hi.2023.17.2.1 · Cited by 21
“30 Prior to CLEAR Harmony, 30 data regarding bempedoic acid were limited to short-term studies with a median follow-up period of 12 weeks.”
MethodDuell, P. B., Banach, M., Catapano, A. L., Laufs, U., Mancini, G. B. J., Ray, K. K., Broestl, C., Zhang, Y., Lei, L., & Goldberg, A. C. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.12.005 · Cited by 21
Self-citationSucato, V., Ortello, A., Comparato, F., Novo, G., & Galassi, A. R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13071882 · Cited by 26
An updated review of lipid‐modifying therapy
Simons, L. A. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50142 · Cited by 18
Bempedoic Acid: A New Non-statin Drug for the Treatment of Dyslipidemia
Wichaiyo, S., & Supharattanasitthi, W. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01075-w · Cited by 17
“The CLEAR-Harmony [29] included 2230 patients with ASCVD or HeFH who had LDL-C ≥ 70 mg/dL despite maximally tolerated statin treatment.”
BackgroundMethodInfluentialHIV: how to manage dyslipidaemia in HIV
Lee, D. C. (2022) · Drugs in Context · doi:10.7573/dic.2021-8-7 · Cited by 19
Pharmacokinetics of current and emerging treatments for hypercholesterolemia
Tomlinson, B., Chan, P., Zhang, Y., Liu, Z., & Lam, C. W. K. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1749261 · Cited by 17
“Having an alternative to statins which is less likely to cause muscle problems would be an advantage and bempedoic acid would appear to be the best candidate for this considering it is selectively activated in the liver and is unlikely to cause muscle problems [121,124].”
BackgroundBempedoic Acid: A New Drug for an Old Problem
Nguyen, D., Du, N., Sulaica, E. M., & Wanat, M. A. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020941083 · Cited by 18
Engel, B. J., Preusch, K., Brown, C., Cramer, C. T., & Shoup, R. E. (2020) · Journal of Chromatography B · doi:10.1016/j.jchromb.2020.122291 · Cited by 19
Bempedoic Acid for Lowering LDL Cholesterol
Honigberg, M. C., & Natarajan, P. (2019) · JAMA · doi:10.1001/jama.2019.16598 · Cited by 16
Biscetti, F., Cecchini, A. L., Rando, M. M., Nardella, E., Gasbarrini, A., Massetti, M., & Flex, A. (2021) · Atherosclerosis Plus · doi:10.1016/j.athplu.2021.10.003 · Cited by 17
Metadata
- Authors
- Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M.
- Affiliations
- Baylor College of Medicine (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-03-14
- Volume
- 380
- Issue
- 11
- Pages
- 1022-1032
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2922038538
- Cited by
- 807
- References
- 20
- Citations by year
- 2026: 77 · 2025: 87 · 2024: 114 · 2023: 143 · 2022: 116 · 2021: 107 · 2020: 107 · 2019: 53
- FWCI
- 91.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- bempedoic acid, LDL cholesterol lowering, ATP-citrate lyase inhibitor, hypercholesterolemia, atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, statin therapy, gout, adverse events, drug safety, lipid-lowering therapy, long-term treatment, gout risk, statin intolerance
- MeSH terms
- Aged, Apolipoproteins B, ATP Citrate (pro-S)-Lyase, C-Reactive Protein, Cholesterol, Dicarboxylic Acids, Drug Therapy, Combination, Fatty Acids, Female, Humans, Hypercholesterolemia, Hypoglycemic Agents, Cholesterol, LDL, Male, Middle Aged, Peptide Fragments, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.